ExcelFin Acquisition Corp.
XFIN
NASDAQ Global Market9.24
USD
-2.06
- -
CIK
0001852749
ISIN
US30069X1028
CUSIP
30069X102
Return %
Stock
S&P500
1Y
-13.08
18.21
3Y
-4.45
63.29
5Y
-4.45
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joseph D. Ragan III
- Full Time Employees
- 4
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 473 Jackson Street San Francisco CA United States of America 94111
- IPO Date
- Dec 16, 2021
- CIK
- 0001852749
- Website
- excelfinacquisitioncorp.com
- Similar Companies
- Business
- ExcelFin Acquisition Corp. ExcelFin Acquisition Corp. is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, with a focus on U.S. and Canadian-domiciled companies in financial technology, fintech software, technology, media, telecommunications, and healthcare sectors; its sponsors include Grand Fortune Capital, LLC, an affiliate of an investment group experienced in significant M&A transactions in these areas, and Fin Venture Capital, a private equity firm specializing in fintech software. The company, founded in 2021 and headquartered in New York, completed its initial public offering on October 21, 2021, raising $230 million in proceeds through underwriters including UBS, EXOS Securities, and KeyBanc Capital Markets. ExcelFin Acquisition Corp. does not generate revenue from operations but pursues value creation through strategic business combinations supported by rigorous due diligence, transparent disclosures, and sponsor expertise in high-growth industries. In its most significant recent development, ExcelFin Acquisition Corp. completed a business combination with Baird Medical, a leading microwave ablation medical device developer and provider in China that recently expanded into the U.S. market following FDA 510(k) clearances, on October 1, 2024; the transaction, initially announced on June 26, 2023, and valued at a pro forma enterprise value of approximately $370 million assuming certain redemptions, resulted in the formation of Baird Medical Investment Holdings Limited (PubCo), with shares and warrants commencing trading on Nasdaq under the tickers BDMD and BDMDW on October 2, 2024. Shareholder approval for the merger and related charter amendments was secured at a special meeting on September 26, 2024, with approximately 99.9% of votes cast in favor and high attendance representing 91.36% of voting capital stock; upon closing, Baird Medical founders and Grand Fortune Capital, LLC subscribed to a $4,900,000 convertible preferred investment in the company. Prior to closing, the company extended its combination deadline multiple times, including amendments to its charter and promissory notes with its sponsor ExcelFin SPAC LLC through December 25, 2024, and received a Nasdaq delisting notice for non-compliance with minimum publicly held shares requirements, for which it sought a compliance plan.
Baird Medical and ExcelFin Acquisition Corp Complete Business Combination
Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement
Baird Medical and ExcelFin Acquisition Corp Announce Strategic Update to Business Combination Terms to Reinforce Long-Term Value Creation Opportunity and Alignment with Shareholders
ExcelFin Acquisition Corp. Announces Adjournment of Special Meeting